Ute Pantke - STADA Arzneimittel Member of the Supervisory Board
Executive
Dr. Ute Pantke is Member of the Supervisory Board and Employee Representative of STADA Arzneimittel AG effective June 4, 2014. She serves as Director Special Brand Projects, Wettenberg. She is a Member of the Strategy Committee. since 2014.
| Age | 60 |
| Tenure | 10 years |
| Professional Marks | Ph.D |
| Phone | 49 6101 603 0 |
| Web | http://www.stada.de |
STADA Arzneimittel Management Efficiency
The company has return on total asset (ROA) of 6.39 % which means that it generated a profit of $6.39 on every $100 spent on assets. This is normal as compared to the sector avarege. Similarly, it shows a return on equity (ROE) of 22.55 %, meaning that it generated $22.55 on every $100 dollars invested by stockholders. STADA Arzneimittel's management efficiency ratios could be used to measure how well STADA Arzneimittel manages its routine affairs as well as how well it operates its assets and liabilities.The company has accumulated 1.73 B in total debt with debt to equity ratio (D/E) of 2.58, implying the company greatly relies on financing operations through barrowing. STADA Arzneimittel has a current ratio of 1.46, which is within standard range for the sector. Debt can assist STADA Arzneimittel until it has trouble settling it off, either with new capital or with free cash flow. So, STADA Arzneimittel's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like STADA Arzneimittel sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for STADA to invest in growth at high rates of return. When we think about STADA Arzneimittel's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Malik Ducard | 51 | ||
| Moran Adania | Radcom | N/A | |
| Yolanda Goettsch | Vita Coco | N/A | |
| Edwin NegronCarballo | Celsius Holdings | 62 | |
| Doniel Sutton | 50 | ||
| Kyle Watson | Celsius Holdings | N/A | |
| Brant Burchfield | Celsius Holdings | N/A | |
| Robin Lybeck | Celsius Holdings | N/A | |
| Jeremy King | 54 | ||
| Corey Baker | Vita Coco | 52 | |
| Thierry Chaumont | BCE Inc | N/A | |
| Harel Givon | Radcom | 44 | |
| Gendra Fachrurozi | Vita Coco | N/A | |
| Julia Donnelly | 41 | ||
| Tony Guilfoyle | Celsius Holdings | N/A | |
| Richard Mattessich | Celsius Holdings | N/A | |
| Guy Shemesh | Radcom | 50 | |
| Paul Wiseman | Celsius Holdings | N/A | |
| Wanjiku Walcott | 53 | ||
| Christine Flores | 45 | ||
| Tonny Mahadarta | Vita Coco | 33 | |
Management Performance
| Return On Equity | 22.55 | |||
| Return On Asset | 6.39 |
STADA Arzneimittel Leadership Team
Elected by the shareholders, the STADA Arzneimittel's board of directors comprises two types of representatives: STADA Arzneimittel inside directors who are chosen from within the company, and outside directors, selected externally and held independent of STADA. The board's role is to monitor STADA Arzneimittel's management team and ensure that shareholders' interests are well served. STADA Arzneimittel's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, STADA Arzneimittel's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Carl Oetker, Member of the Supervisory Board | ||
| JanNicolas Garbe, Member of the Supervisory Board | ||
| Dieter Koch, Member of the Supervisory Board | ||
| Eckhard Brueggemann, Member of the Supervisory Board | ||
| Mark Keatley, CFO, Member of the Executive Board | ||
| Ralph Grobecker, Managing Director of OTC segment | ||
| Martin Abend, Chairman of the Supervisory Board | ||
| Matthias Wiedenfels, Chief Bus. Devel. and Central Services Officer and Member of Executive Board | ||
| Arnold Hertzsch, Member of the Supervisory Board | ||
| Halil Duru, Member of the Supervisory Board | ||
| Tina Mueller, Member of the Supervisory Board | ||
| Engelbert Willink, Chairman of the Executive Board, CEO | ||
| Barthold Piening, Chief Technical Operations Officer, Member of the Executive Board | ||
| Steffen Wagner, Member of the Management Board, Head of Europe | ||
| Helmut Kraft, CFO and Member of Executive Board | ||
| Ute Pantke, Member of the Supervisory Board | ||
| Carsten Cron, Member of the Management Board, Head Emerging Markets | ||
| Frank Seiler, IR Contact Officer | ||
| Hartmut Retzlaff, Chairman of The Executive Board | ||
| Bernhard Duettmann, CFO | ||
| Miguel Pagan, Member of the Executive Board | ||
| Claudio Albrecht, Chairman of the Executive Board, CEO | ||
| Michael Siefke, Member of the Supervisory Board | ||
| Leslie Iltgen, Vice President Investor Relations | ||
| Eric Cornut, Member of the Supervisory Board | ||
| Peter Goldschmidt, Chairman of the Executive Board | ||
| Robert Knerr, Member of the Management Board, Head of Business Development | ||
| Jens Steegers, Member of the Supervisory Board | ||
| Birgit Kudlek, Member of the Supervisory Board | ||
| Guenter Au, Chairman of the Supervisory Board | ||
| Constantin Meyer, Member of the Supervisory Board | ||
| Rolf Hoffmann, Member of the Supervisory Board | ||
| Markus Metzger, Director of Investor Relations | ||
| Benjamin Kunstler, Member of the Supervisory Board | ||
| Gunnar Riemann, Member of the Supervisory Board | ||
| Bruno Schick, Member of the Supervisory Board |
STADA Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is STADA Arzneimittel a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 22.55 | |||
| Return On Asset | 6.39 | |||
| Profit Margin | 9.00 % | |||
| Current Valuation | 6.87 B | |||
| Shares Outstanding | 62.26 M | |||
| Shares Owned By Institutions | 0.30 % | |||
| Price To Earning | 22.46 X | |||
| Price To Book | 4.54 X | |||
| Price To Sales | 2.11 X | |||
| Revenue | 2.69 B |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the STADA Arzneimittel information on this page should be used as a complementary analysis to other STADA Arzneimittel's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Other Consideration for investing in STADA OTC Stock
If you are still planning to invest in STADA Arzneimittel check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the STADA Arzneimittel's history and understand the potential risks before investing.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |